迪哲医药筹划香港上市 加速创新药全球化布局提升国际竞争力

Core Viewpoint - Dige Pharmaceutical Co., Ltd. (stock code: 688192) announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and brand image [1] Group 1: Announcement Details - The second meeting of the second board of directors was held on December 24, 2025, where the proposal for issuing H-shares was approved [1] - The issuance aims to deepen the company's global strategic layout and improve its international brand image and core competitiveness [1] - The company will complete the issuance and listing within 24 months of the shareholders' meeting resolution or an extended period, subject to regulatory approvals [1] Group 2: Regulatory Compliance - The issuance must comply with the Company Law, Securities Law, and relevant regulations from the Hong Kong Stock Exchange and other regulatory bodies [1] - The company is actively discussing specific work related to the issuance with relevant intermediaries, although details such as the proposed share issuance ratio are yet to be determined [1]